<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher
  PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
    <PublisherImprintName>Humana Press</PublisherImprintName>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
      <SeriesSubTitle Language="En">Methods and Protocols</SeriesSubTitle>
      <SeriesAbbreviatedTitle>Methods Molecular Biology</SeriesAbbreviatedTitle>
    </SeriesInfo>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="All" TocLevels="0">
        <BookID>978-1-60327-931-4</BookID>
        <BookTitle>Neural Cell Transplantation</BookTitle>
        <BookSubTitle>Methods and Protocols</BookSubTitle>
        <BookVolumeNumber>549</BookVolumeNumber>
        <BookSequenceNumber>549</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-931-4</BookDOI>
        <BookTitleID>160368</BookTitleID>
        <BookPrintISBN>978-1-60327-930-7</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-931-4</BookElectronicISBN>
        <BookEdition>1</BookEdition>
        <BookChapterCount>16</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="L" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="L16008" Priority="1" Type="Secondary">Cell Biology</BookSubject>
          <BookSubject Code="L16010" Priority="2" Type="Secondary">Stem Cells</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor>
            <EditorName DisplayOrder="Western">
              <GivenName>David</GivenName>
              <FamilyName>Gordon</FamilyName>
            </EditorName>
            <Contact>
              <Email>d.gordon@bristol.ac.uk</Email>
            </Contact>
          </Editor>
          <Editor>
            <EditorName DisplayOrder="Western">
              <GivenName>Neil J.</GivenName>
              <FamilyName>Scolding</FamilyName>
            </EditorName>
            <Contact>
              <Phone>+440177918-6632</Phone>
              <Email>n.j.scolding@tesco.net</Email>
            </Contact>
          </Editor>
          <Affiliation ID="AffID1">
            <OrgDivision>Frenchay Hospital</OrgDivision>
            <OrgName>University of Bristol</OrgName>
            <OrgAddress>
              <City>Bristol</City>
              <Postcode>BS16 1LE</Postcode>
              <Country>United Kingdom</Country>
            </OrgAddress>
          </Affiliation>
          <Affiliation ID="AffID2">
            <OrgDivision>Frenchay Hospital</OrgDivision>
            <OrgName>University of Bristol</OrgName>
            <OrgAddress>
              <City>Bristol</City>
              <Postcode>BS16 1LE</Postcode>
              <Country>United Kingdom</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Part ID="Part1">
        <PartInfo OutputMedium="All" TocLevels="0">
          <PartID>1</PartID>
          <PartSequenceNumber>1</PartSequenceNumber>
          <PartTitle>Introductory Reviews</PartTitle>
          <PartChapterCount>3</PartChapterCount>
          <PartContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-931-4</BookID>
            <BookTitle>Neural Cell Transplantation</BookTitle>
          </PartContext>
        </PartInfo>
        <Chapter ID="Chap3" Language="En">
          <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="All" TocLevels="0">
            <ChapterID>3</ChapterID>
            <ChapterNumber>3</ChapterNumber>
            <ChapterDOI>10.1007/978-1-60327-931-4_3</ChapterDOI>
            <ChapterSequenceNumber>3</ChapterSequenceNumber>
            <ChapterTitle Language="En">Human Trials for Neurodegenerative Disease</ChapterTitle>
            <ChapterFirstPage>33</ChapterFirstPage>
            <ChapterLastPage>47</ChapterLastPage>
            <ChapterCopyright>
              <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
              <CopyrightYear>2009</CopyrightYear>
            </ChapterCopyright>
            <ChapterHistory>
              <RegistrationDate>
                <Year>2009</Year>
                <Month>1</Month>
                <Day>5</Day>
              </RegistrationDate>
              <OnlineDate>
                <Year>2009</Year>
                <Month>3</Month>
                <Day>23</Day>
              </OnlineDate>
            </ChapterHistory>
            <ChapterGrants Type="Regular"><MetadataGrant Grant="OpenAccess"/><AbstractGrant Grant="OpenAccess"/><BodyPDFGrant Grant="Restricted"/><BodyHTMLGrant Grant="Restricted"/><BibliographyGrant Grant="Restricted"/><ESMGrant Grant="Restricted"/></ChapterGrants><ChapterContext>
              <SeriesID>7651</SeriesID>
              <PartID>1</PartID>
              <BookID>978-1-60327-931-4</BookID>
              <BookTitle>Neural Cell Transplantation</BookTitle>
            </ChapterContext>
          </ChapterInfo>
          <ChapterHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1_3" CorrespondingAffiliationID="Aff1_3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Claire</GivenName>
                  <GivenName>M.</GivenName>
                  <FamilyName>Kelly</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>kellycm@cardiff.ac.uk</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff2_3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>O.J.</GivenName>
                  <FamilyName>Handley</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2_3" CorrespondingAffiliationID="Aff2_3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>A.E.</GivenName>
                  <FamilyName>Rosser</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1_3">
                <OrgDivision>Brain Repair Group</OrgDivision>
                <OrgName>School of Biosciences</OrgName>
                <OrgAddress>
                  <Street>Museum Avenue</Street>
                  <Postcode>CF10 3US</Postcode>
                  <City>Cardiff</City>
                  <Country>UK</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2_3">
                <OrgDivision>Department of Neurology and Medical Genetics, School of Medicine</OrgDivision>
                <OrgName>University of Cardiff</OrgName>
                <OrgAddress>
                  <State>Cardiff</State>
                  <Country>UK</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1_3" Language="En" OutputMedium="All">
              <Heading>Summary</Heading>
              <Para>The lack of disease-modifying treatments currently available for not just some but most neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, and even stroke, helps explain increasing interest in cell-based therapies. One key aim of such treatment is to replace neurons or glia lost as a result of the disease, with a view to the cells integrating functionally within the host tissue in order to reconstruct neural circuitry. Clinical trials using primary human fetal tissue as a cell source commenced in Parkinson’s disease (PD) in the 1980s; currently, comparable neural transplantation trials in Huntington’s disease are underway. Disappointing results of later controlled trials in PD illustrated not least the vital importance of methodological issues relating to the structure and implementation of clinical trials, and these issues will be considered here in more depth.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Key words</Heading>
              <Keyword>Neural transplantation</Keyword>
              <Keyword>Huntington’s disease</Keyword>
              <Keyword>Parkinson’s disease</Keyword>
              <Keyword>Stem cell therapy</Keyword>
            </KeywordGroup>
          </ChapterHeader>
          <Body>
            <Section1 ID="Sec1_3">
              <Heading>Introduction</Heading>
              <Para>Human neurodegenerative disorders such as Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), and stroke are caused by a loss of neurons and/or glia. Treatment of these devastating neurological diseases is limited and the lack of a clear mechanism by which such diseases are manifest restricts the treatment modalities that can be considered, as specific targets are not yet identified. Thus, disease-modifying treatments are not yet available for most of these conditions. In the light of this there is considerable interest in neural transplantation as a ­potential thera­peutic strategy. The aim of neural transplantation is to replace the neurons or glia that have been lost as a result of the disease with a view to the cells integrating and synapsing, in the case of neurons, with the host tissue in order to reconstruct the remaining host circuitry. In addition to this, implanted cells may also be used to supply factors such as growth factors or for gene therapy. In the case of stroke models, implantation of certain stem cell types appears to function by encouraging mobilisation of the endogenous stem cell pool.</Para>
              <Para>To date, the most success in terms of achieving circuit reconstruction has been when donor cells are procured from primary foetal tissue obtained from elective termination of pregnancy. However, the logistical and ethical issues associated with the use of this tissue have prevented widespread application. Therefore, alternative donor cell sources are being actively explored, one such cell source being stem cells. Stem cells have the potential to self-propagate, thus generating large numbers of cells, whilst retaining the capacity to differentiate into mature phenotypes. These properties make them an attractive renewable potential source of donor cells.</Para>
            </Section1>
            <Section1 ID="Sec2_3">
              <Heading>Stem and Precursor Cells as Potential Donor Cell Sources (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig1">1</InternalRef>)</Heading>
              <Para>There are many different definitions and categories of stem cell, leading to a somewhat confusing nomenclature. An embryonic stem (ES) cell is derived from the inner cell mass of the blastocyst and has the potential to differentiate into any cell type of the body. Significant ethical disputes have been associated with the derivation and use of ES cells, including concerns over the use of human embryos and fears related to human cloning. As a result of these ethical issues, many countries have restricted or banned ES cell research. Nevertheless, other countries have actively ­supported the development of ES cell research because of the perceived therapeutic benefit in various diseases. Some countries, such as the United Kingdom, allow cloning of human embryos for therapeutic purposes but impose tight regulations to preclude their use for reproductive cloning.<Figure Category="Standard" Float="Yes" ID="Fig1">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>A schematic that illustrates the major sources of stem cells under consideration for production of donor cells for neural transplantation. Stem cells derived from the developing brain are already lineage restricted to produce cells of a neural phenotype, but most other sources need to be manipulated to produce neural cells, and other cell types need to be eliminated. For all stem cell sources (including neural stem cells after more than 1–2 passages), directing the cells to the precise neural phenotype needed for use in specific neurodegenerative conditions remains a major challenge.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-931-4_3_Fig1_HTML.jpg" Format="JPEG" Rendition="HTML" Type="LinedrawHalftone"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para>ES cells can be expanded in culture to generate large populations of cells. Differentiation to tissue-specific lineages can be achieved by exogenous means. For example, ES cell proliferation is maintained in the presence of serum and LIF (leukaemia inhibitory factor), but on removal of serum and LIF from the media the cells have been found to default to a neural lineage. The precise mechanisms that guide the differentiation of a stem cell towards a specific mature phenotype depend on the phenotype in question. For example, for dopaminergic neurons to be gene-rated it has been shown that sonic hedgehog (Shh) and retinoic acid (RA) are amongst a number of important factors, but that the doses and timing of exposure of the cells to these factors are important. Learning to recapitulate in vitro such events in order to “direct” the differentiation of these cells to a particular cell type is complex.</Para>
              <Para>However, there has been progress in achieving specific dopa­minergic neuron differentiation of ES-derived neurons with reports of 16–35% tyrosine hydroxylase (TH) positive neurons being generated by the addition of specific factors to the culture medium (<CitationRef CitationID="CR1_3">1</CitationRef>–<CitationRef CitationID="CR4_3">4</CitationRef>). Expression of the transcription factor Nurr1 enhances the differentiation of ES cells into dopaminergic neurons with reports of 80% TH-positive neurons being generated (<CitationRef CitationID="CR5_3">5</CitationRef>–<CitationRef CitationID="CR9_3">9</CitationRef>). However, many of these studies have based their results on the expression of one marker, TH. Whilst this is present in dopaminergic neurons it does not differentiate between the catecholamines dopamine, noradrenaline, and adrenaline and does not indicate that the cells are functional. In many cases, detailed analysis of TH cells for additional markers such as dopamine receptors, dopamine synthesising enzymes, and storage and uptake molecules (<CitationRef CitationID="CR5_3">5</CitationRef>, <CitationRef CitationID="CR7_3">7</CitationRef>) needs to be performed to characterise these cells more fully. A recent study reports successful dopaminergic neuron differentiation from mouse ES cells, using step-wise protocols similar to those described earlier, both in vitro and following transplantation into a rodent model of PD (<CitationRef CitationID="CR10_3">10</CitationRef>). Proving that similar protocols are effective for human ES cells is crucial, and similar in vitro results have been obtained using a similar step-wise protocol, including Nurr1 expression and co-culture with immortalized asytocytes, for human ES cells (<CitationRef CitationID="CR11_3">11</CitationRef>). Although there is convincing demonstration in this study of the conversion of substantial numbers of hES cells into dopaminergic neurons in vitro (largely gauged by TH staining), the behavioural effects are less easy to evaluate and have been subject to criticism (<CitationRef CitationID="CR12_3">12</CitationRef>). Less is known about the ability of ES cells to generate striatal-like cells for conditions such as HD. Differentiating the cells with chemically defined media resulted in a cell population expressing neural fate characteristics typical of the forebrain such <Emphasis Type="Italic">Dlx5</Emphasis>, <Emphasis Type="Italic">Dlx1</Emphasis>, <Emphasis Type="Italic">Lhx5</Emphasis>, <Emphasis Type="Italic">Tbr1</Emphasis>, <Emphasis Type="Italic">Pax6</Emphasis>, <Emphasis Type="Italic">Dbx1</Emphasis>, <Emphasis Type="Italic">Gsh2</Emphasis>, <Emphasis Type="Italic">and Gsh1</Emphasis> whereas differentiating them to alternative fates was temporally restricted due to a loss of responsiveness to positional cues (<CitationRef CitationID="CR13_3">13</CitationRef>). In the presence of FGF-2 during the first 8 days in culture these cells maintain a largely neuronal fate. However, with successive passaging an ontogenic drift towards gliogenesis is evident (<CitationRef CitationID="CR14_3">14</CitationRef>). Another important issue is the potential of ES cells to form tetracarcinomas, since remaining undifferentiated ES cells in grafted cell suspension can continue to divide forming tumours. For example, Bjorklund et al. grafted a mouse ES cell line into a rat model of PD and reported that 5 out of 25 grafts formed teratoma-like tumours with resulting death of the animals (<CitationRef CitationID="CR15_3">15</CitationRef>). One method for eliminating undifferentiated cells is by the introduction of suicide genes, such as the <Emphasis Type="Italic">E. coli gpt</Emphasis> and herpes thymidine kinase (<Emphasis Type="Italic">HSVtk</Emphasis>), into the cells prior to transplantation. The plasmid vector also contained a neomycin resistance gene that allowed selection of the undifferentiated ES cells, as differentiated cells in the presence of the neomycin resistance gene would be resistant to the effects of ganciclovir. Undifferentiated HSVtk-positive cells that continue to proliferate can then be destroyed by the conversion of prodrug nucleoside ganciclovir to its phosphorylated form, which is then incorporated into the DNA of replicating cells resulting in apoptosis of the cells (<CitationRef CitationID="CR16_3">16</CitationRef>, <CitationRef CitationID="CR17_3">17</CitationRef>). The functionality and efficacy of the differentiated cells will also have to be addressed as well as the possibility of rejection before they can be considered for clinical trials.</Para>
              <Para>Induced pluripotent stem (iPS) cells are a pluripotent population of cells that can be derived from adult somatic cells. They were first produced in mouse in 2006 (<CitationRef CitationID="CR18_3">18</CitationRef>) and subsequently in human in 2007 (<CitationRef CitationID="CR19_3">19</CitationRef>, <CitationRef CitationID="CR20_3">20</CitationRef>) by transducing adult and embryonic fibroblasts with defined factors such as Nanog, Oct4 and Sox2. These cells have presented with characteristics that are very similar if not identical to ES cells and they are an attractive alternative cell source for cell based therapies given that they can be derived from the patients own fibroblast, thereby overcoming the ethical issues associated with the use of ES cells. Much work is required to identify ways of isolating these cells without the need for modification and to further develop these cells for clinical use (for review see (<CitationRef CitationID="CR21_3">21</CitationRef>))</Para>
              <Para>Tissue-specific stem cells such as neural stem cells are derived from neural tissue and are therefore already committed to a neural lineage. It is not clear in all cases that such cells retain the properties of a true stem cell when cultured in vitro and it may be considered more correct to refer to these cells as neural precursor cells. The restriction of differentiated neural stem cells to phenotypes of a neural lineage makes them interesting as a donor cell source for CNS transplantation. Neural precursor cells expand in vitro in the presence of growth factors such as FGF-2 and EGF and form free-floating spheres of cells referred to as neurospheres. These cells have the potential to differentiate into the three cell types of the central nervous system: neurons, glia, and oligodendrocytes. However, such cells have proven less easy to direct towards a specific phenotype than have ES cells (<CitationRef CitationID="CR18_3">22</CitationRef>–<CitationRef CitationID="CR20_3">24</CitationRef>) and a further problem with neural stem cells is that they appear to have limited proliferative and neurogenic potential, which may restrict their therapeutic application (<CitationRef CitationID="CR21_3">25</CitationRef>, <CitationRef CitationID="CR22_3">26</CitationRef>).</Para>
            </Section1>
            <Section1 ID="Sec3_3">
              <Heading>Clinical Trials</Heading>
              <Para>Clinical trials of primary human foetal tissue (i.e., developing cells taken directly from the foetal brain without any manipulation or expansion in culture) are important in paving the way for trials of stem and precursor cell transplantation by demonstrating that cell replacement can be safe and effective in neurodegenerative disease. Foetal cells from the appropriate brain region (e.g. the ventral mesencephalic region for PD) are already committed to the required phenotype and so can provide proof of principle that the cell replacement approach is valid. Clinical trials are ongoing for PD and early trials are now underway for HD based on extensive experimental work in animal models. The PD trials that began in the late 1980s used primary human foetal mesencephalic tissue as the host tissue and transplanted it into the host striatum, which is the target area of these cells. Placing a graft into the substantia nigra is not viable, as the cells are unable to reliably project the distance from the substantia nigra to their targets in the striatum. The mesencephalic tissue contains fate-committed dopaminergic neuroblasts, which have the capacity to differentiate into fully mature dopaminergic neurones following transplantation, provided that the biological principles arising from animal work are adhered to. These include harvesting tissue between specific gestational ages and the optimisation of tissue preparation methodologies as described earlier. If one considers the PD trials in which these principles are taken into account and which use good longitudinal assessment, then results to date in the PD trials have demonstrated improvements in a range of motor skills in some patients, and many, but not all, of the patients have been able to reduce or even eliminate their daily intake of <Emphasis Type="SmallCaps">l</Emphasis>-dopa (<CitationRef CitationID="CR23_3">27</CitationRef>, <CitationRef CitationID="CR24_3">28</CitationRef>). However, there is variability in the success of this approach, which may be a direct result of variations in transplant methodology as well as differences in patient selection criteria (<CitationRef CitationID="CR25_3">29</CitationRef>–<CitationRef CitationID="CR27_3">31</CitationRef>). Recent trials have also highlighted the possibility of dyskinetic side effects in some patients (<CitationRef CitationID="CR25_3">29</CitationRef>), and the reason for these is currently a topic of active investigation (<CitationRef CitationID="CR28_3">32</CitationRef>).</Para>
              <Para>Parallel clinical trials of neural transplantation in HD are at a much earlier stage than the PD trials and are currently underway in a small number of centres around the world. The French trial, based in Créteil, was the first to provide efficacy data, based on systematic long-term evaluation of their patients (<CitationRef CitationID="CR29_3">33</CitationRef>). Three of the five patients, having received bilateral striatal implants, were reported to show substantial improvement over several years (<CitationRef CitationID="CR30_3">34</CitationRef>). More recently there has been an expansion of the French trial to include other French-speaking regions in Europe and a total of 40 patients have now received transplants and are currently undergoing follow-up with no efficacy data available as yet. In another study in Florida, 6 of 7 patients appeared to show improvement but one declined significantly, so that the overall group changes were not significant (<CitationRef CitationID="CR31_3">35</CitationRef>). One patient died after 18 months due to cardiovascular disease, and postmortem analysis of this patient’s brain showed surviving graft tissue with evidence of striatal cell differentiation and appeared to be unaffected by the underly-ing disease progression and free of immune attack (<CitationRef CitationID="CR26_3">30</CitationRef>, <CitationRef CitationID="CR32_3">36</CitationRef>). In the same study three patients developed subdural haemor-rhages and two required surgical drainage probably due to the relatively advanced disease stage in this study compared with others (<CitationRef CitationID="CR31_3">35</CitationRef>). Small numbers of patients have received grafts in several other centres with reports of safety (<CitationRef CitationID="CR33_3">37</CitationRef>, <CitationRef CitationID="CR34_3">38</CitationRef>), and although efficacy studies are underway in these centres, systematic reports have not yet been published.</Para>
              <Para>The initial studies of cell transplantation in PD and HD are providing accumulating evidence of the conditions for safety and preliminary evidence for efficacy. However, the limited availability of foetal tissue and the difficulty in ensuring the high degree of standardisation and quality control when a continuous source of fresh donor tissue is required from elective abortion limits the widespread use of neural transplantation as a practical therapy. Ethical and legislative concerns about abortion and the large number of donors required to support each operation already restrict the number of patients who can receive grafts to a few specialist centres in a restricted number of countries. Moreover, the shifting preference for medical rather than surgical abortions may further limit the availability of tissues to supply even the limited number of programmes already in progress. These issues have stimulated the search for alternative sources of donor cells or tissue that circumvent the problems associated with primary foetal tissue collection.</Para>
              <Para>To date there have been no reported systematic clinical studies of stem/precursor cell transplants in PD or HD, although there have been clinical studies of a variety of renewable cell sources in other neurodegenerative diseases. For example, phase I and phase II clinical trials for stroke have commenced using hNT cells and immunosuppressive treatment for 8 weeks. These cells are post-mitotic immature neurons generated from the immortalized NT2 cell line derived from a human teratocarcinoma (<CitationRef CitationID="CR35_3">39</CitationRef>). The trial was a very small one with only 14 patients receiving transplants in the phase II trial and therefore efficacy cannot be taken from the data. However, it was noted that only 6 patients of the 14 receiving transplants showed improvement on the European stroke scale albeit a non-significant improvement, although significant improvements were seen on some of the secondary neurological outcome measures (<CitationRef CitationID="CR36_3">40</CitationRef>–<CitationRef CitationID="CR39_3">43</CitationRef>). From this study further trials can be initiated taking into account the lessons learnt. Bone marrow-derived stromal cells have also been used in a clinical trial; however, in this instance the cells were infused intravenously and a slight improvement on the patients clinical scale was reported (<CitationRef CitationID="CR40_3">44</CitationRef>). More recently HUCB cells have been approved for clinical trials in traumatic brain injury in children. Xenotransplantation of porcine-derived neural precursor cells into patients with stroke has also been carried out. In this instance 4 years after transplantation 2 of the 5 patients showed functional improvement but only one was significant. One major difference between this and the previous hNT trial is that no immunosuppression was administered; instead, the cells were pre-treated with an anti-major histocompatibility complex class 1 antibody based on preclinical animal experiments.</Para>
            </Section1>
            <Section1 ID="Sec4_3">
              <Heading>Preparation of Cells for Clinical Trials</Heading>
              <Para>Prior to the commencement of clinical trials it is imperative that there are sufficient pre-clinical data to back up the progression to clinical trials. In the case of neural transplantation the pre-clinical data need to be of the highest quality and verified in more than one lab. We consider transplantation experiments in animal models of the disease in question, to demonstrate graft survival, appropriate graft differentiation, and convincing evidence of behavioural improvement to be essential before considering clinical application. Having accumulated sufficient data, all steps in the process of cell preparation are validated under good manufacturing practice (GMP) conditions. This is a prerequisite of all cell preparations for human use under the EU directive; see later. Therefore, all processes in the preparation of a tissue sample for transplantation must be carried out using specified products that have been tested and validated for the purpose. The process itself must be carried out in a GMP facility, which is equivalent to a pharmaceutical grade clean room and is therefore governed by strict rules and regulations all of which are outlined in the directive and which are licensed in the UK by the HTA (human tissue authority). Effectively, this ensures that the tissue/cell source being used for transplantation is handled in the cleanest possible way, thereby reducing as far as possible the risk of any contamination to the cells prior to the transplantation procedure. Regular checks are carried out to ensure that there has been no change to the degree of cleanliness and where necessary steps are taken to rectify any issues. This involves regular decontamination of the facility and measuring air pressure and particle levels within and around the working area all of which must be clearly documented.</Para>
              <Para>Having established a cell source that can be maintained under GMP conditions, the cells may then be deposited to the stem cell bank for long-term storage (<ExternalRef>
                  <RefSource>http://www.ukstemcellbank.org.uk/</RefSource>
                  <RefTarget Address="http://www.ukstemcellbank.org.uk/" TargetType="URL"/>
                </ExternalRef>). The UK stem cell bank is funded by the MRC and is not involved in stem cell biology research to avoid conflicts of interest. Cell lines deposited to the bank are well characterised, and further characterisation where necessary can be carried out by the stem cell bank itself.</Para>
              <Para>Clinical trials of cell therapy must follow frameworks set out by clinical and research governance to ensure the protection and promotion of the health and well-being of the subject at all times. Successful frameworks embody clear lines of responsibility and accountability, the implementation of the highest possible standards of clinical care and a constant dynamic of improvement. There are a large number of regulatory organisations and systems in place to authorise, manage, and review the conduct of clinical trials across countries. The following section provides an overview of current regulations, guidelines and authorities employed to ensure the proper conduct of clinical trials of cell therapy.</Para>
              <Para>A European Union (EU) directive is a legislative act that applies to EU member states (currently 27 European countries). A directive requires the member states to achieve a particular result without laying down the means of achieving that result. Here, we describe two EU directives that are relevant to clinical trials of cell therapy.</Para>
            </Section1>
            <Section1 ID="Sec5_3">
              <Heading>EU Directive 2001/20/EC Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use</Heading>
              <Para>The EU directive 2001/20/EC came into force on May 1, 2004. The purpose of this directive is to enhance the protection of human subjects enrolled in clinical trials of medicinal products, to ensure quality of conduct, and to standardise regulation and conduct of clinical trials across Europe. Paramount to the purpose of a clinical trial is to establish the safety and efficacy of a therapeutic intervention using one or more medicinal products. All trials must be designed, conducted, and reported in accordance with the principles of good clinical practice (GCP), ensuring the protection of human rights and dignity. The directive sets out the laws, regulations, and administrative procedures that must be adhered to when undertaking clinical trials of medicinal products for human use. Each clinical trial must obtain a single favourable opinion from a legally constituted Research Ethics Committee. During the conduct of a clinical trial, statutory inspections should be conducted by authorities able to verify acceptable levels of efficacy and safety of medicines and medical devices, and compliance with the standards of GCP. In the UK a government agency known as the Medicines and Healthcare products Regulatory Agency (MHRA) administers, issues and reports on the conduct of clinical trials. Clinical trials must follow regulated procedures to monitor adverse reactions, known as pharmacovigilance. This system activates the immediate cessation of a trial with an unacceptable level of risk and exchanges information between Member States using Eudravigilance and EudraCT (a database of al clinical trials commencing in the EU from May 1, 2004). Each clinical trial of an investigational medicinal product (IMP) is required to obtain a EudrACT number. Given the potential adverse reactions to any IMP, provisions should be made for insurance or indemnity to cover the liability of the investigator and sponsor.</Para>
            </Section1>
            <Section1 ID="Sec6_3">
              <Heading>EU DIRECTIVE 2004/23/EC on Setting Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Preservation, Storage, and Distribution of Human Tissues and Cells</Heading>
              <Para>The use of human tissues and cells for transplantation has become a strong focus for therapeutic intervention within neurodegenerative diseases. The Directive only applies to the use of human tissue and cells used for clinical trials to the human body; it does not apply to in vitro research experiments or use in animal models of disease. It is essential that the quality and safety of these substances is maintained, in particular to prevent the transmission of diseases. Donated tissues and cells must be procured, tested, processed, preserved and stored in accordance with validated and approved safety measures. A unified framework of standard operating procedures (SOPs) is required to regulate the highest quality of tissue and cells for use in transplantation. The procurement and testing of tissue and cells should be executed by appropriately trained and experienced individuals within laboratory conditions that have received accreditation, authorisation, and licensing by the regulatory body. To promote the highest possible standard of tissue and cells for use in human clinical trials, the Directive insists that the handling, storage, and preparation of substances meets with GMP. GMP refers to highly specified conditions of laboratory practice and regulation put in place to ensure successful production and quality control of the therapeutic product.</Para>
              <Para>In light of the EU directive, the UK Human Tissue Act (2004) has set out a new legal framework for the storage and use of tissue from the living, and the removal, storage, and use of tissues and organs from the dead. The Human Tissue Act also covers residual tissue that has been obtained following clinical and diagnostic procedures. In the UK, the HTA is the regulatory body for all matters concerning the removal, storage, use, and disposal of human tissue for scheduled purposes. The HTA (<ExternalRef>
                  <RefSource>www.hta.gov.uk</RefSource>
                  <RefTarget Address="http://www.hta.gov.uk" TargetType="URL"/>
                </ExternalRef>) provides advice and guidance on the Human Tissue Act, issues codes of practice and is responsible for licensing establishments. The fundamental principle of the HTA is that of consent in relation to the retention and use of living patients’ organs and tissue for particular purposes beyond their diagnosis and treatment, and consent surrounding the removal, retention, and use of tissue from those who have died (where consent is obtained either by those individuals in life, or after death by someone nominated by or close to them). The codes of practice are guidelines that should be applied and adhered to by individuals undertaking relevant activities. The only exception where an HTA licence is not required is where tissue is being stored for use in a specific ethically approved project and is not retained after that project for unspecified future use. The licence permits the specified activity to take place within a specified location under the supervision of the designated individuals (DI) or corporate body named on the licence. The DI is responsible for ensuring that delegated individuals adhere to regulated SOPs. The HTA commands that host organizations are responsible for obtaining consent, ethical approval, ensuring anonymity where necessary, review whether a license is applicable, consolidate holdings, liaise with licensed tissue banks, and handle surplus tissue appropriately.</Para>
            </Section1>
            <Section1 ID="Sec7_3">
              <Heading>The Declaration of Helsinki and GCP</Heading>
              <Para>The Declaration of Helsinki was introduced by the World Medical Association ‘as a statement of ethical standards to provide guidance to physicians and other participants in medical research involving human subjects’. It is the responsibility of the physician to promote and protect the health and rights of the human subject. The impetus of medical research on human subjects should aim to contribute to one of the following areas of investigation: enhance diagnosis, management, treatment or prevention of the disease, to understand the aetiology and the pathogenesis of the disease. Study investigators are expected to be conversant with ethical, legal, and regulatory requirements for research on human subjects in their own countries as well as relevant international requirements.</Para>
              <Para>GCP is an internationally harmonised standard based on the Declaration of Helsinki. It is a standard of practice that should be integrated into clinical investigations involving the participation of human subjects. The guidelines set out the responsibilities, procedures, and processes that should be integrated into clinical trials to assure ethical and scientific integrity, whilst also serving to protect the rights, safety, and well-being of the subjects. Finally, compliance with GCP recommendations maximises the credibility and accuracy of the data extrapolated from the trial.</Para>
            </Section1>
            <Section1 ID="Sec8_3">
              <Heading>Independent Review Board</Heading>
              <Para>According to the Declaration of Helsinki research that includes experimental procedures involving human subjects should be ‘submitted for consideration, comment, guidance, and where appropriate, approval to a specially appointed ethical review committee, which must be independent of the investigator, the sponsor or any other kind of undue influence’. GCP recom-mends that the independent review board (IRB) should be an independent body (a review board or a committee, institu-tional, regional, national or supranational), consisting of medical professionals and non-medical members who collectively have the qualifications and experience to assess the scientific, medical, and ethical aspects of the proposed trial. The responsibility of the IRB is to protect the rights, safety, and well-being of human subjects involved in a trial. The committee is expected to review and approve the trial protocol following consideration of, among other things, the suitability of the investigator(s), site facilities, and the procedures to collect and retain data, and also the processes in place to obtain and document informed consent of the trial subjects. IRBs should conform to the laws and regulations of the country in which the research is performed.</Para>
            </Section1>
            <Section1 ID="Sec9_3">
              <Heading>Outcome Measures</Heading>
              <Para>Cell therapy in neurodegenerative disease aims to restore brain circuitry and function by surgical replacement of the cells lost as a consequence of progressive neurodegenerative disease. The clinically beneficial effect of cell therapy is dependent on two main issues: first, whether the neural graft will survive and replace lost neurons in the place(s) where required, and second, whether the neural graft can integrate into the host neuronal circuitry and restore normal function. Assessing the true efficacy of any cell therapy depends on sensitive and reliable outcome measures. Ideally, an assessment battery to assess efficacy of stem cell therapy would utilise clinical and biological markers collected systematically over a longitudinal period. To date, previous and on-going clinical trials of primary tissue cell therapy in HD and PD have relied on the CAPIT-HD and CAPIT-PD protocols, respectively (CAPIT: Core Assessment Protocol for Intracerebral Transplantation), capturing longitudinal data on clinical and imaging markers. In spite of these existing protocols, there remains a continued demand for the development of more accurate and reliable outcome measures to assess the scientific and economic feasibility of future cell-based therapy.</Para>
              <Para>A key aspect to the successful execution and completion of a clinical trial relies on measures of quality control and quality assurance. Quality control refers to measures and procedures that are put in place in order to ensure that accuracy and reliability of data, whereas quality assurance refers to the evaluation of the effectiveness of these procedures. Quality control can be implemented through training and administration of SOPs, and quality assurance is maintained through monitoring of data to ensure adherence to GCP (see later), to determine the quality and plausibility of data, and compliance to the study protocol.</Para>
              <Para>The purpose of monitoring clinical trials is twofold: (a) to assure that protection, safety and rights of the subjects are maintained, and (b) to assure the quality and integrity of the data. A trial sponsor carries the responsibility of monitoring and often delegates the task to a contract research organisation. Monitors are required to verify that the study investigators are conversant with the study protocol and plan, competent to execute a well-controlled study with adequate facilities, population sample and time, and to ensure that investigators understand their obligation to obtain the relevant IRB approvals, and informed consent. A key area of importance surrounds monitoring and reporting of adverse events. All clinical trials carry risk to the subject’s safety, and the procedures in place to handle an adverse event or reaction are determined by its severity. In cases of serious events or reactions, investigators must execute a series of actions with strict adherence to SOPs in order to alert and register the event with the appropriate healthcare authorities.</Para>
            </Section1>
            <Section1 ID="Sec10_3">
              <Heading>Useful Sources of Information</Heading>
              <Para>
                <UnorderedList Mark="None">
                  <ItemContent>
                    <Para>Medicines and Healthcare products Regulatory Agency: <ExternalRef>
                        <RefSource>www.mhra.gov.uk</RefSource>
                        <RefTarget Address="http://www.mhra.gov.uk" TargetType="URL"/>
                      </ExternalRef>
                    </Para>
                  </ItemContent>
                  <ItemContent>
                    <Para>Eudract: <ExternalRef>
                        <RefSource>http://eudract.emea.europa.eu</RefSource>
                        <RefTarget Address="http://eudract.emea.europa.eu" TargetType="URL"/>
                      </ExternalRef>
                    </Para>
                  </ItemContent>
                  <ItemContent>
                    <Para>Clinical Trials Toolkit: <ExternalRef>
                        <RefSource>www.ct-toolkit.ac.uk</RefSource>
                        <RefTarget Address="http://www.ct-toolkit.ac.uk" TargetType="URL"/>
                      </ExternalRef>
                    </Para>
                  </ItemContent>
                  <ItemContent>
                    <Para>European Medicines Agency: <ExternalRef>
                        <RefSource>www.emea.europa.eu</RefSource>
                        <RefTarget Address="http://www.emea.europa.eu" TargetType="URL"/>
                      </ExternalRef>
                    </Para>
                  </ItemContent>
                  <ItemContent>
                    <Para>EU Clinical Trials Directive: <ExternalRef>
                        <RefSource>www.eortc.be/Services/Doc/clinical-EU-directive-04-April-01.pdf</RefSource>
                        <RefTarget Address="http://www.eortc.be/Services/Doc/clinical-EU-directive-04-April-01.pdf" TargetType="URL"/>
                      </ExternalRef>
                    </Para>
                  </ItemContent>
                  <ItemContent>
                    <Para>EU Tissue Directive: <ExternalRef>
                        <RefSource>http://europa.eu.int/eurlex/pri/en/oj/dat/2004/l_102/l_1020040407en00480058.pdf</RefSource>
                        <RefTarget Address="http://europa.eu.int/eurlex/pri/en/oj/dat/2004/l_102/l_1020040407en00480058.pdf" TargetType="URL"/>
                      </ExternalRef>
                    </Para>
                  </ItemContent>
                </UnorderedList>
              </Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/978-1-60327-931-4_Chapter_3.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
          <ChapterBackmatter>
            <Bibliography ID="Bib1_3">
              <Heading>References</Heading>
              <Citation ID="CR1_3">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Kawasaki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Mizuseki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Nishikawa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Kaneko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Kuwana</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Nakanishi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Sasai</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity</ArticleTitle>
                  <JournalTitle>Neuron</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>31</FirstPage>
                  <LastPage>40</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11086981</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0896-6273(00)00083-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXnvVGlt78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakanishi S, Sasai Y. (2000). Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron <Emphasis>28</Emphasis>:31–40.</BibUnstructured>
              </Citation>
              <Citation ID="CR2_3">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S-H</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Lumelsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Studer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Auerbach</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>McKay</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells</ArticleTitle>
                  <JournalTitle>Nature Biotechnology</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>675</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10835609</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/76536</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXktlWjs70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lee S-H, Lumelsky N, Studer L, Auerbach JM, McKay R. (2000). Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nature Biotechnology <Emphasis Type="Bold">18</Emphasis>:675–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR3_3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Okabe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Forsberg-Nilsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AC</Initials>
                    <FamilyName>Spiro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Segal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RDG</Initials>
                    <FamilyName>McKay</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro</ArticleTitle>
                  <JournalTitle>Mechanisms of Development</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <FirstPage>89</FirstPage>
                  <LastPage>102</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8892235</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0925-4773(96)00572-2</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XlsFagsrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Okabe S, Forsberg-Nilsson K, Spiro AC, Segal M, McKay RDG. (1996). Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mechanisms of Development <Emphasis Type="Bold">59</Emphasis>:89–102.</BibUnstructured>
              </Citation>
              <Citation ID="CR4_3">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Rolletschek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KM</Initials>
                    <FamilyName>Guan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Czyz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Meyer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Wobus</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Differentia-tion of embryonic stem cell-derived dopaminergic neurons is enhanced by survival-promo-ting factors</ArticleTitle>
                  <JournalTitle>Mechanisms of Development</JournalTitle>
                  <VolumeID>105</VolumeID>
                  <FirstPage>93</FirstPage>
                  <LastPage>104</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11429285</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0925-4773(01)00385-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXks1Omtb4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rolletschek A, Chang H, Guan KM, Czyz J, Meyer M, Wobus AM. (2001). Differentia-tion of embryonic stem cell-derived dopaminergic neurons is enhanced by survival-promo-ting factors. Mechanisms of Development <Emphasis Type="Bold">105</Emphasis>:93–104.</BibUnstructured>
              </Citation>
              <Citation ID="CR5_3">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Chung</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KC</Initials>
                    <FamilyName>Sonntag</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Andersson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>Bjorklund</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JJ</Initials>
                    <FamilyName>Park</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DW</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>UJ</Initials>
                    <FamilyName>Kang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Isacson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KS</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons</ArticleTitle>
                  <JournalTitle>European Journal of Neuroscience</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>1829</FirstPage>
                  <LastPage>38</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12453046</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1460-9568.2002.02255.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chung S, Sonntag KC, Andersson T, Bjorklund LM, Park JJ, Kim DW, Kang UJ, Isacson O, Kim KS. (2002). Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. European Journal of Neuroscience <Emphasis Type="Bold">16</Emphasis>:1829–38.</BibUnstructured>
              </Citation>
              <Citation ID="CR6_3">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Grothe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Timmer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Scholz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Winkler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Nikkhah</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Claus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Itoh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Arenas</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons</ArticleTitle>
                  <JournalTitle>Neurobiology of Disease</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>163</FirstPage>
                  <LastPage>70</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15474354</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.nbd.2004.07.007</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXotlSlsb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Grothe C, Timmer M, Scholz T, Winkler C, Nikkhah G, Claus P, Itoh N, Arenas E. (2004). Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons. Neurobiology of Disease <Emphasis Type="Bold">17</Emphasis>:163–70.</BibUnstructured>
              </Citation>
              <Citation ID="CR7_3">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Auerbach</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Rodriguez-Gomez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Velasco</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Gavin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Lumelsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SH</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Nguyen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Sanchez-Pernaute</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease</ArticleTitle>
                  <JournalTitle>Nature</JournalTitle>
                  <VolumeID>418</VolumeID>
                  <FirstPage>50</FirstPage>
                  <LastPage>6</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12077607</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nature00900</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XltVantrc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, et al. (2002). Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature <Emphasis Type="Bold">418</Emphasis>:50–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR8_3">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JY</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HC</Initials>
                    <FamilyName>Koh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JY</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MY</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YC</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HY</Initials>
                    <FamilyName>Chung</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Son</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YS</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Studer</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression</ArticleTitle>
                  <JournalTitle>Journal of Neurochemistry</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>1443</FirstPage>
                  <LastPage>54</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12787064</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1471-4159.2003.01780.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXkslOktLw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kim JY, Koh HC, Lee JY, Chang MY, Kim YC, Chung HY, Son H, Lee YS, Studer L, et al. (2003). Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression. Journal of Neurochemistry <Emphasis Type="Bold">85</Emphasis>:1443–54.</BibUnstructured>
              </Citation>
              <Citation ID="CR9_3">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Wagner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Akerud</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Castro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PC</Initials>
                    <FamilyName>Holm</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Canals</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EY</Initials>
                    <FamilyName>Snyder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Perlmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Arenas</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Induction of a midbrain dopaminergic phenotype in Nurr1- overexpressing neural stem cells by type 1 astrocytes</ArticleTitle>
                  <JournalTitle>Nature Biotechnology</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>653</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10404157</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/10862</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXksFaqt7Y%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wagner J, Akerud P, Castro DS, Holm PC, Canals JM, Snyder EY, Perlmann T, Arenas E. (1999). Induction of a midbrain dopaminergic phenotype in Nurr1- overexpressing neural stem cells by type 1 astrocytes. Nature Biotechnology <Emphasis Type="Bold">17</Emphasis>:653–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR10_3">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Rodriguez-Gomez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JQ</Initials>
                    <FamilyName>Lu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Velasco</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rivera</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Zoghbi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Liow</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Musachio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FT</Initials>
                    <FamilyName>Chin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Toyama</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>918</FirstPage>
                  <LastPage>28</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17170065</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.2006-0386</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXls1Kmtro%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rodriguez-Gomez JA, Lu JQ, Velasco I, Rivera S, Zoghbi SS, Liow JS, Musachio JL, Chin FT, Toyama H, et al. (2007). Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells <Emphasis Type="Bold">25</Emphasis>:918–28.</BibUnstructured>
              </Citation>
              <Citation ID="CR11_3">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NS</Initials>
                    <FamilyName>Roy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Cleren</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SK</Initials>
                    <FamilyName>Singh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Yang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MF</Initials>
                    <FamilyName>Beal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Goldman</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes</ArticleTitle>
                  <JournalTitle>Nature Medicine</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <FirstPage>1259</FirstPage>
                  <LastPage>68</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17057709</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nm1495</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhtFKlsLfL</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. (2006). Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nature Medicine <Emphasis Type="Bold">12</Emphasis>:1259–68.</BibUnstructured>
              </Citation>
              <Citation ID="CR12_3">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NS</Initials>
                    <FamilyName>Christophersen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Large stem cell grafts could lead to erroneous interpretations of behavioral results?</ArticleTitle>
                  <JournalTitle>Nature Medi-cine</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>118</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nm0207-118a</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhsVyktL8%3D</Handle>
                  </Occurrence>
                  <BibComments>author reply 119</BibComments>
                </BibArticle>
                <BibUnstructured>Christophersen NS, Brundin P. (2007). Large stem cell grafts could lead to erroneous interpretations of behavioral results?. Nature Medi-cine <Emphasis Type="Bold">13</Emphasis>:118; author reply 119.</BibUnstructured>
              </Citation>
              <Citation ID="CR13_3">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>IA</Initials>
                    <FamilyName>Bouhon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Kato</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Chandran</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ND</Initials>
                    <FamilyName>Allen</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Neural differentiation of mouse embryonic stem cells in chemically defined medium</ArticleTitle>
                  <JournalTitle>Brain Research Bulletin 15</JournalTitle>
                  <VolumeID>68</VolumeID>
                  <FirstPage>62</FirstPage>
                  <LastPage>75</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.brainresbull.2005.08.022</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXht1OlsLjP</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bouhon IA, Kato H, Chandran S, Allen ND. (2005). Neural differentiation of mouse embryonic stem cells in chemically defined medium. Brain Research Bulletin 15 <Emphasis Type="Bold">68</Emphasis>:62–75.</BibUnstructured>
              </Citation>
              <Citation ID="CR14_3">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>IA</Initials>
                    <FamilyName>Bouhon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Joannides</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Kato</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Chandran</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ND</Initials>
                    <FamilyName>Allen</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Embryonic stem cell-derived neural progenitors display temporal restriction to neural patterning</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>1908</FirstPage>
                  <LastPage>13</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16627686</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.2006-0031</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhtFKiurfK</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bouhon IA, Joannides A, Kato H, Chandran S, Allen ND. (2006). Embryonic stem cell-derived neural progenitors display temporal restriction to neural patterning. Stem Cells <Emphasis Type="Bold">24</Emphasis>:1908–13.</BibUnstructured>
              </Citation>
              <Citation ID="CR15_3">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>Bjorklund</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>SÂnchez-Pernaute</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Chung</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Andersson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IY</Initials>
                    <FamilyName>Ching Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KSP</Initials>
                    <FamilyName>McNaught</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AL</Initials>
                    <FamilyName>Brownell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BG</Initials>
                    <FamilyName>Jenkins</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Wahlested</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model</ArticleTitle>
                  <JournalTitle>Proceedings of National Academy of Science USA</JournalTitle>
                  <VolumeID>99</VolumeID>
                  <FirstPage>2344</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.022438099</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XitVSrurg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bjorklund LM, SÂnchez-Pernaute R, Chung S, Andersson T, Ching Chen IY, McNaught KSP, Brownell AL, Jenkins BG, Wahlested C, et al. (2002). Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proceedings of National Academy of Science USA <Emphasis Type="Bold">99</Emphasis>:2344–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR16_3">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MU</Initials>
                    <FamilyName>Fareed</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FL</Initials>
                    <FamilyName>Moolten</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Suicide gene transduction sensitizes murine embryonic and human mesenchymal stem cells to ablation on demand – A fail-safe protection against cellular misbehavior</ArticleTitle>
                  <JournalTitle>Gene Therapy</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>955</FirstPage>
                  <LastPage>62</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12085244</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.gt.3301771</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xksl2mt78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fareed MU, Moolten FL. (2002). Suicide gene transduction sensitizes murine embryonic and human mesenchymal stem cells to ablation on demand – A fail-safe protection against cellular misbehavior. Gene Therapy <Emphasis Type="Bold">9</Emphasis>:955–62.</BibUnstructured>
              </Citation>
              <Citation ID="CR17_3">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Schuldiner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Itskovitz-Eldor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Benvenisty</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Selective ablation of human embryonic stem cells expressing a “suicide” gene</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>257</FirstPage>
                  <LastPage>65</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12743320</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.21-3-257</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXkvFGnu7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schuldiner M, Itskovitz-Eldor J, Benvenisty N. (2003). Selective ablation of human embryonic stem cells expressing a “suicide” gene. Stem Cells<Emphasis Type="Bold">21</Emphasis>:257–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR18_3">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Thakahashi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Yamanaka</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</ArticleTitle>
                  <JournalTitle>Cell</JournalTitle>
                  <VolumeID>126</VolumeID>
                  <FirstPage>663</FirstPage>
                  <LastPage>676</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.cell.2006.07.024</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Thakahashi K, Yamanaka S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676.</BibUnstructured>
              </Citation>
              <Citation ID="CR19_3">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Takahashi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Tanabe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Ohnuki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Narita</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Ichisaka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Tomoda</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Yamanaka</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Induction of pluripotent stem cells from adult human fibroblasts by defined factors</ArticleTitle>
                  <JournalTitle>Cell</JournalTitle>
                  <VolumeID>131</VolumeID>
                  <FirstPage>861</FirstPage>
                  <LastPage>872</LastPage>
                  <Occurrence Type="PID">
                    <Handle>18035408</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.cell.2007.11.019</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhsVCntbbK</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872.</BibUnstructured>
              </Citation>
              <Citation ID="CR20_3">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Yu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Vodyanik</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Smuga-Otto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Antosiewicz-Bourget</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Frane</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Tian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Nie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GA</Initials>
                    <FamilyName>Jonsdottir</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Ruotti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Stewart R</Initials>
                    <FamilyName>Slukvin</FamilyName>
                    <Suffix>II</Suffix>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Thomsen</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Induced pluripotent stem cell lines derived from human somatic cells</ArticleTitle>
                  <JournalTitle>Science</JournalTitle>
                  <VolumeID>318</VolumeID>
                  <FirstPage>1917</FirstPage>
                  <LastPage>1920</LastPage>
                  <Occurrence Type="PID">
                    <Handle>18029452</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1126/science.1151526</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhsVGjsLbN</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, Thomsen JA. (2007). Induced pluripotent stem cell lines derived from human somatic cells. <Emphasis Type="Italic">Science</Emphasis>
                  <Emphasis Type="Bold">318</Emphasis>:1917–1920.</BibUnstructured>
              </Citation>
              <Citation ID="CR21_3">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Zhao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GQ</Initials>
                    <FamilyName>Daley</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">From fibroblasts to iPS cells: induced pluripotency by defined factors</ArticleTitle>
                  <JournalTitle>J Cell Biochem</JournalTitle>
                  <VolumeID>105</VolumeID>
                  <FirstPage>949</FirstPage>
                  <LastPage>955</LastPage>
                  <Occurrence Type="PID">
                    <Handle>18668528</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/jcb.21871</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXhtl2hsLbO</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhao R, Daley GQ. (2008). From fibroblasts to iPS cells: induced pluripotency by defined factors. J Cell Biochem 105:949–955.</BibUnstructured>
              </Citation>
              <Citation ID="CR22_3">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Cesnulevicius</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Timmer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Wesemann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Thomas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Barkhausen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Grothe</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Nucleofection is the most efficient nonviral transfection method for neuronal stem cells derived from ventral mesencephali with no changes in cell composition or dopaminergic fate</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>2776</FirstPage>
                  <LastPage>91</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16902196</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.2006-0176</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXkslCkug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Cesnulevicius K, Timmer M, Wesemann M, Thomas T, Barkhausen T, Grothe C. (2006). Nucleofection is the most efficient nonviral transfection method for neuronal stem cells derived from ventral mesencephali with no changes in cell composition or dopaminergic fate. Stem Cells <Emphasis Type="Bold">24</Emphasis>:2776–91.</BibUnstructured>
              </Citation>
              <Citation ID="CR23_3">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Anderson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Burnstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>He</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Luce</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Furlong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Foltynie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Sykacek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DK</Initials>
                    <FamilyName>Menon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Caldwell</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Gene expression changes in long term expanded human neural progenitor cells passaged by chopping lead to loss of neurogenic potential in vivo</ArticleTitle>
                  <JournalTitle>Experiments in Neurology</JournalTitle>
                  <VolumeID>204</VolumeID>
                  <FirstPage>512</FirstPage>
                  <LastPage>24</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.expneurol.2006.12.025</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXjslSktbw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Anderson L, Burnstein RM, He X, Luce R, Furlong R, Foltynie T, Sykacek P, Menon DK, Caldwell MA. (2007). Gene expression changes in long term expanded human neural progenitor cells passaged by chopping lead to loss of neurogenic potential in vivo. Experiments in Neurology <Emphasis Type="Bold">204</Emphasis>:512–24.</BibUnstructured>
              </Citation>
              <Citation ID="CR24_3">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HJ</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Sugimori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Nakafuku</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CN</Initials>
                    <FamilyName>Svendsen</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1</ArticleTitle>
                  <JournalTitle>Experiments in Neurology</JournalTitle>
                  <VolumeID>203</VolumeID>
                  <FirstPage>394</FirstPage>
                  <LastPage>405</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.expneurol.2006.08.029</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhtVKnt7Y%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kim HJ, Sugimori M, Nakafuku M, Svendsen CN. (2007). Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1. Experiments in Neurology <Emphasis Type="Bold">203</Emphasis>:394–405.</BibUnstructured>
              </Citation>
              <Citation ID="CR25_3">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Andersson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JB</Initials>
                    <FamilyName>Jensen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Parmar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Guillemot</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Bjorklund</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2</ArticleTitle>
                  <JournalTitle>Development</JournalTitle>
                  <VolumeID>133</VolumeID>
                  <FirstPage>507</FirstPage>
                  <LastPage>16</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16396906</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1242/dev.02224</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28Xit1KmtL8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Andersson E, Jensen JB, Parmar M, Guillemot F, Bjorklund A. (2006). Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2. Development <Emphasis Type="Bold">133</Emphasis>:507–16.</BibUnstructured>
              </Citation>
              <Citation ID="CR26_3">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Zietlow</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Pekarik</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RJ</Initials>
                    <FamilyName>Armstrong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Tyers</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SB</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Rosser</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">The survival of neural precursor cell grafts is influenced by in vitro expansion</ArticleTitle>
                  <JournalTitle>Journal of Anatomy</JournalTitle>
                  <VolumeID>207</VolumeID>
                  <FirstPage>227</FirstPage>
                  <LastPage>40</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16185247</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1469-7580.2005.00449.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXhtFSnsbzM</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zietlow R, Pekarik V, Armstrong RJ, Tyers P, Dunnett SB, Rosser AE. (2005). The survival of neural precursor cell grafts is influenced by in vitro expansion. Journal of Anatomy <Emphasis Type="Bold">207</Emphasis>:227–40.</BibUnstructured>
              </Citation>
              <Citation ID="CR27_3">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Hagell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease</ArticleTitle>
                  <JournalTitle>Journal of Neuropathology and Experimental Neurology</JournalTitle>
                  <VolumeID>60</VolumeID>
                  <FirstPage>741</FirstPage>
                  <LastPage>52</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11487048</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3MvktFelug%3D%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1093/jnen/60.8.741</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Hagell P, Brundin P. (2001). Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. Journal of Neuropathology and Experimental Neurology <Emphasis Type="Bold">60</Emphasis>:741–52.</BibUnstructured>
              </Citation>
              <Citation ID="CR28_3">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CW</Initials>
                    <FamilyName>Olanow</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Kordower</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TB</Initials>
                    <FamilyName>Freeman</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Fetal nigral transplantation as a therapy for Parkinson’s disease</ArticleTitle>
                  <JournalTitle>Trends in Neurosciences</JournalTitle>
                  <VolumeID>19</VolumeID>
                  <FirstPage>102</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9054056</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0166-2236(96)80038-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XhtlSntro%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Olanow CW, Kordower JH, Freeman TB. (1996). Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends in Neurosciences <Emphasis Type="Bold">19</Emphasis>:102–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR29_3">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CR</Initials>
                    <FamilyName>Freed</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PE</Initials>
                    <FamilyName>Greene</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RE</Initials>
                    <FamilyName>Breeze</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WY</Initials>
                    <FamilyName>Tsai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>DuMouchiel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Kao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Dillon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Winfield</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Culver</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Transplantation of embryonic dopamine neurons for severe Parkinson’s disease</ArticleTitle>
                  <JournalTitle>The New England Journal of Medicine</JournalTitle>
                  <VolumeID>344</VolumeID>
                  <FirstPage>710</FirstPage>
                  <LastPage>19</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11236774</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM200103083441002</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3M7ltFCisQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchiel W, Kao R, Dillon S, Winfield H, Culver S, et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. The New England Journal of Medicine <Emphasis Type="Bold">344</Emphasis>:710–19.</BibUnstructured>
              </Citation>
              <Citation ID="CR30_3">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TB</Initials>
                    <FamilyName>Freeman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Cicchetti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Hauser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TW</Initials>
                    <FamilyName>Deacon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XJ</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Hersch</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GM</Initials>
                    <FamilyName>Nauert</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PR</Initials>
                    <FamilyName>Sanberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Kordower</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Transplanted fetal striatum in Huntington’s disease: Phenotypic development and lack of pathology</ArticleTitle>
                  <JournalTitle>Proceedings of the National Academy of Sciences</JournalTitle>
                  <VolumeID>97</VolumeID>
                  <FirstPage>13877</FirstPage>
                  <LastPage>82</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.97.25.13877</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXoslynsb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, et al. (2000). Transplanted fetal striatum in Huntington’s disease: Phenotypic development and lack of pathology. Proceedings of the National Academy of Sciences <Emphasis Type="Bold">97</Emphasis>:13877–82.</BibUnstructured>
              </Citation>
              <Citation ID="CR31_3">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Lindvall</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Widner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rehncrona</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Gustavii</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Frackowiak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KL</Initials>
                    <FamilyName>Leenders</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Sawle</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JC</Initials>
                    <FamilyName>Rothwell</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1990</Year>
                  <ArticleTitle Language="En">Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease</ArticleTitle>
                  <JournalTitle>Science</JournalTitle>
                  <VolumeID>247</VolumeID>
                  <FirstPage>574</FirstPage>
                  <LastPage>7</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2105529</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1126/science.2105529</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3c7ktVOhtA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, et al. (1990). Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science <Emphasis Type="Bold">247</Emphasis>:574–7.</BibUnstructured>
              </Citation>
              <Citation ID="CR32_3">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Hagell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Piccine</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Björklund</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rehncrona</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Widner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Crabb</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Pavese</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WH</Initials>
                    <FamilyName>Oertel</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Dyskinesias following neural transplantation in Parkinson’s disease</ArticleTitle>
                  <JournalTitle>Nature Neuroscience</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>627</FirstPage>
                  <LastPage>8</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12042822</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xkslyisr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hagell P, Piccine P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, et al. (2002). Dyskinesias following neural transplantation in Parkinson’s disease. Nature Neuroscience <Emphasis Type="Bold">5</Emphasis>:627–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR33_3">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AC</Initials>
                    <FamilyName>Bachoud-Levi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Gaura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Brugieres</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JP</Initials>
                    <FamilyName>Lefaucheur</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MF</Initials>
                    <FamilyName>Boisse</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Maison</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Baudic</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Ribeiro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Bourdet</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Effect of fetal neural transplants in patients with Huntington’s disease 6 years after surgery: A long-term follow-up study</ArticleTitle>
                  <JournalTitle>Lancet Neurology</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>303</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16545746</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S1474-4422(06)70381-7</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, Baudic S, Ribeiro MJ, Bourdet C, et al. (2006). Effect of fetal neural transplants in patients with Huntington’s disease 6 years after surgery: A long-term follow-up study. Lancet Neurology <Emphasis Type="Bold">5</Emphasis>:303–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR34_3">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AC</Initials>
                    <FamilyName>Bachoud-Levi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Hantraye</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Peschanski</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Fetal neural grafts for Huntington’s disease: A prospective view</ArticleTitle>
                  <JournalTitle>Movement Disorders</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>439</FirstPage>
                  <LastPage>44</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12112189</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/mds.10117</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bachoud-Levi AC, Hantraye P, Peschanski M. (2002). Fetal neural grafts for Huntington’s disease: A prospective view. Movement Disorders <Emphasis Type="Bold">17</Emphasis>:439–44.</BibUnstructured>
              </Citation>
              <Citation ID="CR35_3">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Hauser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PR</Initials>
                    <FamilyName>Sandberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TB</Initials>
                    <FamilyName>Freeman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AJ</Initials>
                    <FamilyName>Stoessl</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Bilateral human fetal striatal transplantation in Huntington’s disease</ArticleTitle>
                  <JournalTitle>Neurology</JournalTitle>
                  <VolumeID>58</VolumeID>
                  <FirstPage>687</FirstPage>
                  <LastPage>685</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11889229</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1212/WNL.58.5.687</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD387ptFWjug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hauser RA, Sandberg PR, Freeman TB, Stoessl AJ. (2002). Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology <Emphasis Type="Bold">58</Emphasis>:687–685.</BibUnstructured>
              </Citation>
              <Citation ID="CR36_3">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TB</Initials>
                    <FamilyName>Freeman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Hauser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PR</Initials>
                    <FamilyName>Sanberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Saporta</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Neural transplantation for the treatment of Huntington’s disease</ArticleTitle>
                  <JournalTitle>Progress in Brain Research</JournalTitle>
                  <VolumeID>127</VolumeID>
                  <FirstPage>405</FirstPage>
                  <LastPage>11</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11142038</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0079-6123(00)27019-2</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3M7gsFKqsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Freeman TB, Hauser RA, Sanberg PR, Saporta S. (2000). Neural transplantation for the treatment of Huntington’s disease. Progress in Brain Research <Emphasis Type="Bold">127</Emphasis>:405–11.</BibUnstructured>
              </Citation>
              <Citation ID="CR37_3">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>OV</Initials>
                    <FamilyName>Kopyov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Jacques</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KS</Initials>
                    <FamilyName>Eagle</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Fetal transplantation for the treatment of neurodegenerative diseases – Current status and future potential</ArticleTitle>
                  <JournalTitle>CNS Drugs</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>77</FirstPage>
                  <LastPage>83</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00023210-199809020-00001</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kopyov OV, Jacques S, Eagle KS. (1998). Fetal transplantation for the treatment of neurodegenerative diseases – Current status and future potential. CNS Drugs <Emphasis Type="Bold">9</Emphasis>:77–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR38_3">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Rosser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Barker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Harrower</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Watts</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Farrington</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Burnstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DK</Initials>
                    <FamilyName>Menon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Gillard</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Unilateral transplantation of human primary fetal tissue in four patients with Huntington’s disease: NEST-UK safety report ISRCTN no 36485475</ArticleTitle>
                  <JournalTitle>Journal of Neurology, Neurosurgery, and Psychiatry</JournalTitle>
                  <VolumeID>73</VolumeID>
                  <FirstPage>678</FirstPage>
                  <LastPage>85</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12438470</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1136/jnnp.73.6.678</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD38nnvVGktQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, et al. (2002). Unilateral transplantation of human primary fetal tissue in four patients with Huntington’s disease: NEST-UK safety report ISRCTN no 36485475. Journal of Neurology, Neurosurgery, and Psychiatry <Emphasis Type="Bold">73</Emphasis>:678–85.</BibUnstructured>
              </Citation>
              <Citation ID="CR39_3">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PW</Initials>
                    <FamilyName>Andrews</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Damjanov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Simon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GS</Initials>
                    <FamilyName>Banting</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Carlin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NC</Initials>
                    <FamilyName>Dracopoli</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Fogh</FamilyName>
                  </BibAuthorName>
                  <Year>1984</Year>
                  <ArticleTitle Language="En">Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2</ArticleTitle>
                  <JournalTitle>Differentiation in vivo and in vitro. Laboratory Investigation</JournalTitle>
                  <VolumeID>50</VolumeID>
                  <FirstPage>147</FirstPage>
                  <LastPage>62</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2cXhsFCgu70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Andrews PW, Damjanov I, Simon D, BantingGS, Carlin C, Dracopoli NC, Fogh J. (1984). Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Laboratory Investigation <Emphasis Type="Bold">50</Emphasis>:147–62.</BibUnstructured>
              </Citation>
              <Citation ID="CR40_3">
                <CitationNumber>40.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Kondziolka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GK</Initials>
                    <FamilyName>Steinberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Wechsler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Meltzer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Elder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Gebel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Decesare</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Jovin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Zafonte</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Neurotransplantation for patients with subcortical motor stroke: A phase 2 randomized trial</ArticleTitle>
                  <JournalTitle>Journal of Neurosurg</JournalTitle>
                  <VolumeID>103</VolumeID>
                  <FirstPage>38</FirstPage>
                  <LastPage>45</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.3171/jns.2005.103.1.0038</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kondziolka D, Steinberg GK, Wechsler L, Meltzer CC, Elder E, Gebel J, Decesare S, Jovin T, Zafonte R, et al. (2005). Neurotransplantation for patients with subcortical motor stroke: A phase 2 randomized trial. Journal of Neurosurg <Emphasis Type="Bold">103</Emphasis>:38–45.</BibUnstructured>
              </Citation>
              <Citation ID="CR41_3">
                <CitationNumber>41.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Kondziolka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Wechsler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Goldstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Meltzer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KR</Initials>
                    <FamilyName>Thulborn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Gebel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Jannetta</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>DeCesare</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Elder</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Transplantation of cultured human neuronal cellsfor patients with stroke</ArticleTitle>
                  <JournalTitle>Neurology 22</JournalTitle>
                  <VolumeID>55</VolumeID>
                  <FirstPage>565</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1212/WNL.55.4.565</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3cvhsFSjtg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, Jannetta P, DeCesare S, Elder EM, et al. (2000). Transplantation of cultured human neuronal cellsfor patients with stroke. Neurology 22 <Emphasis Type="Bold">55</Emphasis>:565–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR42_3">
                <CitationNumber>42.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Meltzer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Kondziolka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VL</Initials>
                    <FamilyName>Villemagne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Wechsler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Goldstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KR</Initials>
                    <FamilyName>Thulborn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Gebel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Elder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>DeCesare</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Jacobs</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Serial [18F] fluorodeoxyglucose positron emission tomography after human neuronal implantation for stroke</ArticleTitle>
                  <JournalTitle>Neurosurgery</JournalTitle>
                  <VolumeID>49</VolumeID>
                  <FirstPage>586</FirstPage>
                  <LastPage>91</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11523668</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3MvotVSqtg%3D%3D</Handle>
                  </Occurrence>
                  <BibComments>discussion 91–2</BibComments>
<Occurrence Type="DOI">
<Handle>10.1227/00006123-200109000-00011</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Meltzer CC, Kondziolka D, Villemagne VL, Wechsler L, Goldstein S, Thulborn KR, Gebel J,Elder EM, DeCesare S, Jacobs A. (2001). Serial [18F] fluorodeoxyglucose positron emission tomography after human neuronal implantation for stroke. Neurosurgery <Emphasis Type="Bold">49</Emphasis>:586–91; discussion 91–2.</BibUnstructured>
              </Citation>
              <Citation ID="CR43_3">
                <CitationNumber>43.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PT</Initials>
                    <FamilyName>Nelson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Kondziolka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Wechsler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Goldstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Gebel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>DeCesare</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Elder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PJ</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Jacobs</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Clonal human (hNT) neuron grafts for stroke therapy: Neuropathology in a patient 27 months after implantation</ArticleTitle>
                  <JournalTitle>The American Journal of Pathology</JournalTitle>
                  <VolumeID>160</VolumeID>
                  <FirstPage>1201</FirstPage>
                  <LastPage>6</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11943704</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9440(10)62546-1</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nelson PT, Kondziolka D, Wechsler L, Goldstein S, Gebel J, DeCesare S, Elder EM, Zhang PJ, Jacobs A, et al. (2002). Clonal human (hNT) neuron grafts for stroke therapy: Neuropathology in a patient 27 months after implantation. The American Journal of Pathology <Emphasis Type="Bold">160</Emphasis>:1201–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR44_3">
                <CitationNumber>44.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>OY</Initials>
                    <FamilyName>Bang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PH</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Autologous mesenchymal stem cell transplantation in stroke patients</ArticleTitle>
                  <JournalTitle>Annals of Neurology</JournalTitle>
                  <VolumeID>57</VolumeID>
                  <FirstPage>874</FirstPage>
                  <LastPage>82</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15929052</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/ana.20501</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bang OY, Lee JS, Lee PH, Lee G. (2005). Autologous mesenchymal stem cell transplantation in stroke patients. Annals of Neurology <Emphasis Type="Bold">57</Emphasis>:874–82.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ChapterBackmatter>
        </Chapter>
      </Part>
    </Book>
  </Series>
</Publisher>